Latest News about IONS
Recent news which mentions IONS
   2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
   
  
  
  January 04, 2024
  From Benzinga
 
   10 Health Care Stocks Whale Activity In Today's Session
   
  
  
  January 02, 2024
  From Benzinga
 From InvestorPlace
 
   Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
   
  
  
  December 22, 2023
  From Benzinga
 
   New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
   
  
  
  December 22, 2023
  From Benzinga
 From Benzinga
 
   Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
   
  
  
  November 02, 2023
  From Benzinga
 From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
   
  
  
  September 29, 2023
  From Benzinga
 
   Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
   
  
  
  September 27, 2023
  From Benzinga
 
   Analyst Expectations for Ionis Pharmaceuticals's Future
   
  September 27, 2023
  Tickers 
   IONS
  
  
  From Benzinga
 
   Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
   
  September 26, 2023
  Tickers 
   IONS
  
  
  From Benzinga
 
   The 7 Most Hated Stocks by Institutional Traders
   
  
  
  September 20, 2023
  From InvestorPlace
 
   Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
   
  
  
  September 07, 2023
  From Benzinga
 
   Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
   
  
  
  August 07, 2023
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
   
  
  
  July 03, 2023
  From Benzinga
 
   Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
   
  
  
  June 12, 2023
  From Benzinga
 
   Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'
   
  
  
  June 07, 2023
  From Benzinga
 From Benzinga
 From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.